Introduction
In-stent restenosis (ISR) is recently challenging complication of coronary stent implantation in both stable coronary artery disease (CAD) and acute coronary syndrome (ACS). Since coronaroplasty is not only done using balloons, the stent era has pushed invasive cardiology further also to the new era of procedures' complications, including drawback due to ISR [1] . Single nucleotide polymorphism (SNP) is a genetic variation leading to change in one specifi c location causing signifi cant change in coded protein. It leads to over 90% of genetic variation in human species and may vary among different population groups [2] . Linkage between ISR and SNPs may answer the question why in the era of modern cardiology we still need to struggle with repeating invasive procedures. The next question is whether we could isolate these patients and support them with genetic screening and increased number of control visits.
Many factors contribute to CAD, but only some have impact on ISR. SNPs would be a nice marker to examine before we implant stents in stable CAD subject. SNPs of genes coding angiotensin converting enzyme (ACE -rs1799752), angiotensinogen (rs699), basic fi broblast growth factor (bFGF -rs308395) and renin (rs5705) lead to CAD, but not to ISR [3] [4] [5] .
In CAD and ISR SNPs proven correlations exist for genes coding transforming growth factor beta 1 (TGF-β1 -rs1800470), platelet-derived growth factor beta (PDGFB -rs2285094), vascular endothelial growth factor A (VEGF-A -rs699947) and connexin 37 (CX-37 -rs1764391) [3, 6, 7] . ISR was found also among patients with CAD and genetic variant of interleukin 18 (IL-18 -rs187238) -137G/G which has not been proven for -137G/C and -137C/C variants obtained from non-CAD controls [8] . Also endothelial nitric oxide synthase (eNOS -rs1799983) was suspected to contribute to susceptibility of ISR in CAD patients its 298G/T variant was investigated together with glutation peroxidase (GPx-1 rs1050450) 599C/T SNP and both of them were found to play role in ISR significantly [9] . eNOS CAD patients studied in other project were proven that carriers of the 298Asp allele of the eNOS (rs1799983) polymorphism showed a higher frequency of restenosis compared to 298Glu homozygotes [10] . Also cyclin-dependent kinase inhibitor p27 SNP -838C/A (rs36228499) leads to ISR [11] . Cyclin B1 SNPs themselves demostrate higher ISR risk (rs350099, rs350104, and rs164390) [11] . Interesting may seem protective SNP of receptor for advanced glycation end products (RAGE -374T/A -rs1800625) in -374AA lower susceptibility to ISR was found among 276 subjects [12] . All above data are listed in Table 1 showing which genetic polymorphism is connected to CAD and ISR.
Although some fi ndings may hopefully show that a kind of genetic marker perfect for screening for ISR would appear, other are unlikely to become one of them. Genes investigated for ISR and correlating neither with increased prevalence of CAD nor with ISR include: cyclin-dependent kinase inhibitor p27 (rs2066827 and rs34330), epidermal growth factor (EGF rs4444903) [3, 13] . Another case might be research done in the fi eld of cytochrome P450 which is responsible for clopidogrel -leading antiplatellet drug -metabolism. 2015 fi ndings indicated that CYP2C19*2 (rs4244285) allele in Arabic origin subjects with a functional CYP2C19*1 allele showed no linkage with ISR [14] . Involvement of immune system in case of Toll-like receptor 4 (TLR4 rs4986790 and rs4986791) [15] , IL-10 in Chinese Han population (-592 C/A rs1800872) [16] was not supported.
Taking into consideration hormones, blood vessels controlling molecules, immune system particles and oxidative stress-related molecules that may infl uence process of ISR and require further investigation, also by means of genetic analysis from large cohorts of patients worldwide. Already provided data support the thesis of genetic background of higher susceptibility to CAD itself, some to atherosclerosis, also located in other than coronary vessels, but ISR is still in phase of analysis. According to the data yet obtained, genetics may play important role in development of ISR among CAD patients by means of either hormonal (ACE, angiotensinogen) or blood vessels controlling agents (eNOS, GPx-1, CX-37, cyclin, cellular growth factors). Thesis of contribution of immune system, supported by logical assumption about infl ammatory background of atherosclerosis may not be totally correct since IL-18 genetic polymorphism was solely the only one supported by literature. Neither TLR4, nor IL-10 did not match this hypothesis in large investigated groups compared to patients without ISR. Some referential data exclude one another, but looking closely -investigator take into consideration genetically different populations, i.e. Caucasian and Asian groups should not be considered the same in the fi elds of genetic analysis. Different populations although might be (and should be) investigated for fi nding the same SNPs increasing susceptibility to ISR, need to be also checked for their genetic potential to cause CAD fi rst and, which seems crucial yet omitted in plenty of articles -compared to presence of the same SNP among non-CAD patients, not only investigating CAD subjects group. Another issue worth investigation might be differentiation between ISR, increased by genetic susceptibility and stent type. Important information include: do genes play role in ISR development in different types of stents, does the drug covering drug eluting stents matter among patients with higher presence of particular polymorphisms or does type of stent in comparison with higher susceptibility of ISR genetically proved leads to poorer prognosis. That kind of data would be useful as predictive value for ISR and prognosis among CAD patients, furthermore would lead to individualized therapy among patients subjected to coronaroplasty.
